What are the details of your prescription?
Atrovent HFA
Generic Name: Ipratropium Bromide HFA
Drug Category: Anticholinergic
Litigation Alert Level: Medium
This drug has been approved for use by males and females over the age of 18 years old for a maximum duration of 5 years.
| Approved Uses |
|
Indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Atrovent HFA is not indicated for the initial treatment of acute episodes of bronchospasm where rescue therapy is required for rapid response. Two inhalations four times a day, not to exceed 12 inhalations in 24 hours. Atrovent HFA can produce paradoxical bronchospasm that can be life threatening. Atrovent HFA is an anticholinergic and its use may increase intraocular pressure. This may result in precipitation or worsening of narrow-angle glaucoma. Therefore, ATROVENT HFA should be used with caution in patients with narrow angle glaucoma. Atrovent HFA is an anticholinergic and may cause urinary retention. Therefore caution is advised when administering ATROVENT HFA Inhalation Aerosol to patients with prostatic hyperplasia, or bladder-neck obstruction. Hypersensitivity reactions including urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema may occur after the administration of ATROVENT HFA. There is potential for an additive interaction with concomitantly used anticholinergic medications. Therefore, avoid co-administration of ATROVENT HFA with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects. There are no adequate and well-controlled studies of ATROVENT HFA (ipratropium bromide) Inhalation Aerosol in pregnant women. It is not known whether the active component, ipratropium bromide, is excreted in human milk. Because lipid-insoluble quaternary cations pass into breast milk, caution should be exercised when ATROVENT HFA is administered to a nursing mother. |
| Off-label Uses |
|
• Use in patients under the age of 18 years of age. GoToSource • Cystic fibrosis. GoToSource • Non-allergic rhinitis. GoToSource • Adult dosage greater than 12 inhalations in 24 hours. GoToSource • Relief of cold symptoms. GoToSource • Traumatic unilateral vasomotor rhinitis. GoToSource • Gustatory rhinitis. GoToSource • Clozapine-induced hypersalivation. GoToSource |
| Adverse Events |
|
Serious cardiovascular events including cardiovascular mortality. GoToSource Paradoxical bronchoconstriction and impaired cognitive function. GoToSource Strokes. GoToSource Acute urinary retention. GoToSource Urticaria (hives) and angioedema (swelling in deep layers of the skin). GoToSource Precipitation or worsening of narrow-angle glaucoma. GoToSource Mydriasis (pupil dilation). GoToSource |
| Litigation |
|
Lawsuits filed for heart attacks, strokes and death. |
The material contained in GoToPills is for informational purposes only and not intended to replace the judgment, evaluation and treatment of physicians, pharmacists and other healthcare providers. GoToPills does not provide medical advice, diagnoses or treatment. Always seek the advice of your physician or other qualified health provider regarding a medical condition or treatment.
